test, was used; if the result was positive, an HCV RNA and genotype test on the same specimen was performed. Untreated and non-responder patients were treated.

Results: : A total of 938 patients were included, and 409 (44%) could be reached. Out Of these, 16.3% (67) died, 1.7% (7) developed hepatocellular carcinoma, and 6.75% (15) progressed to cirrhosis. We found that 21.7% were candidates for treatment, and the treatment was delivered in two clinic visits with an average time of 29 days (7-69). However, 41% (34) of patients with cirrhosis could not be contacted.

Conclusions: : Program implementation improved the diagnosis and treatment access. Furthermore, it reduces the number of clinical visits and may increase adherence to follow-up. On the other hand, we are concerned that half of the patients were lost on the follow-up and about their progression to cirrhosis rate. If we are looking for different results, we should take different measures.

https://doi.org/10.1016/j.aohep.2023.100937

P-36 RESULTS OF AN AUTOMATIC ALERT SYSTEM FROM MICROBIOLOGY TO LINK DIAGNOSIS TO TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS C

Carlos Alventosa Mateu[1],
María Dolores Ocete Mochón[2],
Juan José Urquijo Ponce[1],
Mercedes Latorre Sánchez[1],
Inmaculada Castelló Miralles[1],
Miguel García Deltoro[3], Enrique Ortega González[4],
María José Bonet Igual[5],
Concepción Gimeno Cardona[2], Moisés Diago Madrid[1]

[1] *Hepatology Unit. Gastroenterology Department. University General Hospital Consortium of Valencia. Valencia, Spain*
[2] *Microbiology Department. University General Hospital Consortium of Valencia. Valencia, Spain*
[3] *Infectious Diseases Department. University General Hospital Consortium of Valencia. Valencia Spain*
[4] *Foundation of the University General Hospital Consortium of Valencia. Valencia, Spain*
[5] *Picassent Penitentiary Medical Department. Valencia, Spain*

Introduction and Objectives: Strategies to simplify the care circuit for patients with the hepatitis C virus (HCV) are vital to achieving its eradication. To achieve this aim, we introduced an electronic system of HCV serology detection to link diagnosis with specialized assistance in order to minimize the loss of patients.

Materials and Methods: A retrospective single-center study of HCV patients developed by Microbiology Department from February 15th, 2020, to December 15th, 2021. In the event of a positive HCV antibody, the anti-HCV core was directly measured by the electronic system. If positive, an encrypted e-mail with the patient data was automatically sent to HCV specialized physicians, who, after evaluating the benefits of antiviral therapy in each patient, contacted them by phone for an appointment. In the first face-to-face consultation FibroScan®, HCV genotype and viral load measurement were performed, and antiviral therapy was prescribed. Patient diagnosis origin and public health characteristics were recorded. We analyzed the association between antiviral therapy prescription and these variables. Statistical significance was set at $p<0.005$.

Results: Of 171 patients identified, with a mean age of 59.6 ± 15.9, 61.5 % of males and 81.2% of Spanish nationals. HCV origin from out-of-hospital settings predominated (50.9%, 87/171), particularly primary care (28.7%), penitentiary (11.6%) and addiction units (8.2%). In all, 43.3% (74/171) were aware of their diagnosis, but 64.9% (48/74) hadn't previously received antiviral therapy. Genotype 1 predominated. We recorded 19.4% (20/103) of patients F3 fibrosis and 27.2% (26/103) F4.

Finally, 58.5% (100/171) attended a physician consultation. They were all treated with pangenotypic interferon-free therapy. A 100% rate of sustained viral response was achieved. The main reasons for not being treated were high comorbidity (43.7%,31/71), not located (23.9%, 17/71), patient refusal to treatment (23.9%,17/71) and death (8.5%,6/71). The sole association found between antiviral therapy and patient variables was that of comorbidities with being untreated (OR=7.14, $p<0.001$).

Conclusions: Our alert system is simple and easily reproducible. It allows for minimizing the loss of HCV patients, even considering it was performed during the COVID-19 pandemic.

https://doi.org/10.1016/j.aohep.2023.100938

P-37 ASSESSMENT OF METABOLIC ASSOCIATED FATTY LIVER DISEASE, ALCOHOLIC LIVER DISEASE, AND DUAL DAMAGE IN APPARENTLY HEALTHY BLOOD BANK INDIVIDUALS

Jorge Emilio Lira-Vera, O Morales-Gutiérrez,
Farid Yael Vargas-Durán,
Pablo Alagón-Fernández Del Campo,
Ana Karen Soto Martínez, Diana Montemira-Orozco,
Andrés Burak-Leipuner, Christian Hinojosa-Segura,
Gabriela Gutiérrez-Reyes, Moisés Martínez-Castillo,
Samantha Sánchez-Valle,
María De Los Ángeles Lemus-Peña,
Daniel Montes De Oca-Ángeles,
Abigail Hernández-Barragán,
Marisela Hernández-Santillán,
María De Fátima Higuera-De La Tijera,
Yadira Lilian Béjar-Ramírez,
José Luis Pérez-Hernández

Gastroenterology and Hepatology Department, Hospital General de México "Dr. Eduardo Liceaga," Mexico City, Mexico

Introduction and Objectives: metabolic syndrome and alcohol consumption are the leading causes of fatty liver disease. Now, a new term called dual damage has emerged. So far, no studies are reporting the prevalence of dual damage in Mexico. This study aimed to determine the prevalence of metabolic associated fatty liver disease, alcoholic liver disease, and dual damage in the healthy population of the blood bank of our center.

Materials and Methods: descriptive, cross-sectional, prolective study. We included donors ≥18 years old. We excluded subjects with known liver disease. Vibration-controlled transient hepatic elastography was the method of estimating steatosis and liver fibrosis. We used descriptive statistics.

Results: 258 donors were included; 129 (50%) have hepatic steatosis: 67 (25.96%) metabolic associated, 31 (12.01%) due to alcohol, and 31 (12.01%) by dual damage. In the metabolic group, S1 was found in 14 subjects (20.90%), S2 in 23 (34.32%), and S3 in 30 (44.78%). 23 (34.32%) were overweight, 23 (34.32%) had obesity grade 1, 11 (16.44%) grade 2, and 5 (7.46%) grade 3. Of the alcohol damage group, 12 (38.70%) had S1, 5 (19.35%) S2, and 13 (41.95%) S3. Beer was the most frequently consumed beverage (61.29%), with the excessive pattern being the most frequent (74.19%), with an average intake of 90.25 grams. 100% of donors with dual damage presented S3 steatosis. Advanced fibrosis was